FDA Approves Xhance for Nasal Polyps
Nasal polyps are common in people with allergies and
asthma. Treatment has included nasal sprays and oral medications, and now we have a new one to add to the list, Xhance (fluticasone propionate).
What is Xhance indicated for?
Xhance is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older. It will be available as a nasal spray in the strength of 93 mcg.
The recommended dose of Xhance is one or two sprays per nostril twice daily. The Xhance delivery system is called the Optinose delivery system. It works to help deliver Xhance deep into the nasal cavity. Be sure to read the instructions before using the delivery system.
Who is at risk for nasal polyps?
Any condition that causes chronic inflammation in the nasal passages or sinus area may increase your risk of developing nasal polyps. The following conditions can put you at a higher risk for nasal polyps: asthma, aspirin sensitivity, allergic fungal sinusitis, cystic fibrosis and Churg-Strauss syndrome.
What are the common side effects associated with Xhance?
Common side effects include nosebleeds, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis. Be sure to speak with your doctor if you experience any of these symptoms for a prolonged period of time.
What is the difference between Xhance and Flonase?
There are several differences between Xhance (fluticasone propionate) and Flonase (fluticasone propionate), including the following:
- The strength of Xhance is 93 mcg per spray whereas the strength of Flonase is 50 mcg per spray.
- Xhance is indicated for the treatment of nasal polyps whereas Flonase is indicated for the management of allergy symptoms.
- Xhance requires a prescription whereas Flonase can now be purchased over-the-counter without a doctor’s prescription.
- Flonase is available in a generic version, as fluticasone propionate, whereas Xhance is only available as a brand name medication.
For more information on Xhance, see the press announcement from the manufacture Optinose here, and the Xhance website here.
Dr. Orrange is a Clinical Associate Professor of Medicine at the University of Southern California, as well as a practicing adult medicine doctor in Los Angeles. She also has a Masters in Public Health from Johns Hopkins University. She does not receive any form of compensation from pharmaceutical manufacturers for the opinions expressed here. Follow her on twitter at 
Roni Shye, PharmD CGP BCACP graduated from Duquesne University and is a licensed pharmacist in the states of Florida, Ohio, and Pennsylvania. Her realm of pharmacy experience includes but is not limited to retail, compounding, and specialty pharmacy. Currently she is a mentor for Strong Women Strong Girls, certified thru APhA in Medication Therapy Management and diabetes, and an active member of The Ohio pharmacists association, LGBT, and the Women's Business Resource Group.
Elizabeth Davis is GoodRx's medical editor and consumer savings expert. She hand-assembled the GoodRx drug database and has researched virtually every available discount program and savings opportunity.